SCHEMBL6604092

SCHEMBL6604092

CCOc1cc(-c2ccccc2)nn1CCOc1cc(-c2ccc[nH]2)ccc1Cl

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.35
NLRP3 Q96P20 1/20 0.34
KMO O15229 2/20 0.34
TP53 P04637 2/20 0.34
MDM2 Q00987 1/20 0.34
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
HPGD P15428 1/20 0.33
HTR2A P28223 2/20 0.32
BACE1 P56817 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
S1PR4 O95977 1/20 0.32
PIN1 Q13526 1/20 0.32
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601258 0.93 HPGD (0.39) HTR2CNLRP3KMOTP53MDM2
SCHEMBL6606680 0.82 MAPT (0.37) HTR2CNLRP3TP53MDM2POLB
SCHEMBL6603641 0.81 KDM4E (0.38) KMOTP53MDM2POLBSMN1; SMN2
SCHEMBL6603543 0.81 ADORA2A (0.36) HTR2CNLRP3KMOTP53MDM2
SCHEMBL6601824 0.81 KDM4E (0.38) TP53MDM2POLBSMN1; SMN2RXFP1
SCHEMBL6805998 0.80 HPGD (0.41) HTR2CNLRP3TP53MDM2POLB
SCHEMBL6602658 0.80 HPGD (0.42) HTR2CNLRP3TP53MDM2POLB
SCHEMBL6603655 0.77 HPGD (0.38) HTR2CTP53MDM2POLBSMN1; SMN2
SCHEMBL6602669 0.76 KDM4E (0.45) POLBSMN1; SMN2ALDH1A1HPGDTDP1
SCHEMBL6603514 0.76 NLRP3 (0.41) NLRP3TP53POLBSMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 HTR2C 2597/4885NLRP3 1134/4885KMO 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.